Onconetix (ONCO) Accounts Payables (2021 - 2026)
Onconetix (ONCO) posted quarterly Accounts Payables of $1.5 million for Q1 2026, down 40.63% year-over-year from $2.6 million in Q1 2025, and down 12.79% quarter-over-quarter from $1.8 million in Q4 2025.
Onconetix (ONCO) Accounts Payables (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Accounts Payables for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 40.63% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 40.63% YoY), while the FY2025 annual figure was $1.8 million, down 53.59% from the prior year.
- Accounts Payables eased to $1.5 million in Q1 2026 per ONCO's latest filing, from $1.8 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.3 million in Q4 2023 and bottomed at $834308.0 in Q3 2022.
- Historically, Accounts Payables has averaged $1.9 million across 5 years, with a median of $1.5 million in 2023.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 253.17% — and 2025, when it sank 53.59%.
- Onconetix's Accounts Payables stood at $1.5 million in 2022, then surged by 253.17% to $5.3 million in 2023, then fell by 28.47% to $3.8 million in 2024, then tumbled by 53.59% to $1.8 million in 2025, then retreated by 12.79% to $1.5 million in 2026.
- Business Quant data shows ONCO's Accounts Payables at $1.5 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.84 Mn |
| Mar 31, 2026 | 1.53 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 2.58 Mn |
| Mar 31, 2025 | 2.58 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 5.30 Mn |
| Sep 30, 2023 | 900,000.00 |
| Jun 30, 2023 | 2.08 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.50 Mn |
| Sep 30, 2022 | 834,308.00 |
| Jun 30, 2022 | 972,971.00 |
| Mar 31, 2022 | 907,538.00 |
| Dec 31, 2021 | 582,605.00 |